Fig. 9

Cavity area ratio compared with the control group, ^##P < 0.01. Compared with the VEGF₁₆₅ group^*P < 0.05, ^**P < 0.01 A. Control group B. Sorafenib group C. VEGF165 group D. Low dose group of OI (0.2 mg·mL⁻¹) E. Middle dose group of OI (0.5 mg·mL⁻¹) F. High dose group of OI (0.8 mg·mL.⁻¹)